Drug Topics
FEBRUARY 11, 2025
Poor cardiometabolic health is associated with cognitive impairment in later life, but there is no clear association between cardiometabolic trajectories and early markers.
PhRMA
FEBRUARY 11, 2025
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
FEBRUARY 11, 2025
Madison Irwin, PharmD, BCPS, discusses the importance of suzetrigines approval in the pain management space and potential challenges or barriers in its adoption.
PharmaVoice
FEBRUARY 11, 2025
What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
FEBRUARY 11, 2025
Tryvio was given FDA approval on March 19, 2024.
Pharmacy Times
FEBRUARY 11, 2025
Pharmacists can recommend vitamin D supplements and vitamin D-rich foods to support healthy pregnancy outcomes.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
The Checkup by Singlecare
FEBRUARY 11, 2025
Meloxicam , sold under the brand name Mobic, is a prescription nonsteroidal anti-inflammatory drug ( NSAID ) used to treat inflammatory conditions like rheumatoid arthritis and osteoarthritis. It is also used off-label (for a use not approved by the Food and Drug Administration) to treat ankylosing spondylitis. Meloxicam is a stronger painkiller than other NSAIDs like ibuprofen and naproxen.
Drug Topics
FEBRUARY 11, 2025
Help your patients overcome tummy troubles with trusted OTC products that relieve bloating, heartburn, and more, promoting smooth and happy digestion.
Pharmaceutical Technology
FEBRUARY 11, 2025
Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront payment of $925m.
Drug Topics
FEBRUARY 11, 2025
Social media can help close the gap on health care information access, but pharmacists still play a large role in diabetes management, especially in therapeutics.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Technology
FEBRUARY 11, 2025
Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease space.
The FDA Law Blog
FEBRUARY 11, 2025
By Larry K. Houck One of the most significant issues facing hospitals and other facilities is the diversion of controlled substances meant for patients by physicians, pharmacists, nurses and other trusted healthcare employees. Recent employee diversion of significant controlled substance quantities from hospitals has resulted in large civil monetary settlements, some in the millions of dollars, and costly compliance remediation programs to resolve allegations.
The Checkup by Singlecare
FEBRUARY 11, 2025
Repatha is the brand name for evolocumab, an FDA-approved monoclonal antibody used to lower cholesterol. In addition to lowering LDL (low-density lipoprotein) cholesterol levels, Repatha helps restore blood flow to the heart, decreasing the risks of heart attack and strokes in people with heart disease. Repatha is often used when medications like statin drugs dont lower cholesterol enough and can be combined with statin medications.
Pharmacy Times
FEBRUARY 11, 2025
Emerging data indicate that COVID-19 is also characterized by inflammation present in the heart and other organs
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
FEBRUARY 11, 2025
Absci and Generate say they use AI to make drugs. Do they?
Pharmacy Times
FEBRUARY 11, 2025
Richard Lewis discusses the critical role pharmacists and health care providers play in ensuring safe administration of IVIG for patients with CIDP.
The Checkup by Singlecare
FEBRUARY 11, 2025
Individual medications are sometimes taken together to increase their positive effects: Tylenol (acetaminophen), aspirin, and caffeine, for example, is a well-known combination that can treat migraine pain better and faster than taking a single pain reliever. But you may not be as familiar with the combination of gabapentin and melatonin. At first glance, these two drugs dont seem to have much in common.
pharmaphorum
FEBRUARY 11, 2025
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
FEBRUARY 11, 2025
Humana posted a $693 million loss in the fourth quarter of 2024, a notable increase from its $541 million loss in the prior-year quarter, according to its earnings report released Tuesday morning.
Pharmacy Times
FEBRUARY 11, 2025
The approval is based on positive clinical trial results that indicated deep and durable reductions in plexiform neurofibroma.
Pharmaceutical Technology
FEBRUARY 11, 2025
The World Health Organization and St Jude Children's Research Hospital have kicked off a programme to distribute cancer medicines to LMICs.
Pharmacy Times
FEBRUARY 11, 2025
Circulating lactate is increased in patients with myelofibrosis and corresponds with the remodeling of lactate export channel monocarboxylate transporter 4, suggesting a link with fibrosis establishment.
STAT
FEBRUARY 11, 2025
KAMPALA, Uganda — Ebola cases in Uganda have risen to nine, while 265 other people were being monitored under quarantine, health authorities said Tuesday. The nine include the first victim, a male nurse who died the day before the outbreak was declared on Jan. 30. That man remains the only fatality.
Fierce Healthcare
FEBRUARY 11, 2025
Walgreens must pay more than $987 million as part of an arbitration award won by a virtual care company, a federal judge ruled Monday. | Walgreens said it is closely evaluating its legal rights and options to challenge both the award and the amount of damages on appeal.
STAT
FEBRUARY 11, 2025
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get straight into another busy news day.
The Checkup by Singlecare
FEBRUARY 11, 2025
Ozempic (semaglutide) is an injectable medication approved by the U.S. Food and Drug Administration (FDA) to treat Type 2 diabetes mellitus and lower the risk of heart attack or stroke in people with Type 2 diabetes and cardiovascular disease. Healthcare providers may also use Ozempic injectables off-label for weight loss management. It falls under the drug classes of antidiabetics and GLP-1 agonists.
pharmaphorum
FEBRUARY 11, 2025
It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet.
Fierce Healthcare
FEBRUARY 11, 2025
The networks other founding members comprise Blue Cross and Blue Shield of North Carolina, CVS Health, Devoted Health, Elevance Health, Geisinger and Highmark Health. Among its goals is to track the outcomes of food as medicine interventions and advocate for the movement with policymakers.
pharmaphorum
FEBRUARY 11, 2025
Looking beyond the scale: Why measures of physical activity should be incorporated into obesity trials to support long-term sustainable weight loss Mike.
Pharmacy Times
FEBRUARY 11, 2025
Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.
Fierce Healthcare
FEBRUARY 11, 2025
A new collaboration between three health plans is aiming to improve primary care in California and reduce physician burnout. | Blue Shield of California, Aetna California and Medi-Cal insurer Health Net are all participating in the California Advanced Primary Care Initiative.
pharmaphorum
FEBRUARY 11, 2025
Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming
The FDA Law Blog
FEBRUARY 11, 2025
By Alan M. Kirschenbaum & Sophia R. Gaulkin Drug manufacturers wont be receiving their first invoices for Medicare Part B and Part D inflation rebates until later this year, but rebates have been accruing since first quarter 2023 for Part B rebates and October 2022 for Part D rebates. To help our readers learn more about these rebates before they confront the first invoices, weve prepared a memo summarizing CMS final rule on the two Medicare inflation rebate programs, which was issued on De
Expert insights. Personalized for you.
457 
Let's personalize your content